

sequence corresponding to the sequence of a 3'-UTR [entire untranslated 3' region (3'-UTR)] of a human or mouse ribonucleotide reductase R1 or R2 mRNA, [of mRNA of a housekeeping gene or a consecutive sequence segment of said 3'UTR], wherein the oligonucleotide exhibits reduced oligonucleotide-oligonucleotide dimer formation, reduced self-complementary interactions and reduced binding potential to said mRNA.

6. The [synthetic] oligonucleotide, or analogue thereof, as set forth in claim 1 [5] wherein the oligonucleotide comprises [has] a sequence corresponding to the [entire] sequence of the 3'-UTR of a human or mouse ribonucleotide reductase R1 mRNA [for the R1 component] as set forth in SEQ ID No: 1 [(SEQ ID No:1) of or segment thereof substantially free of the coding sequence of ribonucleotide reductase protein R1].
7. The [synthetic] oligonucleotide, or analogue thereof, as set forth in claim 6 wherein the oligonucleotide comprises [segment has] a sequence as set forth in SEQ ID Nos: 44, 45, 46, 47, 48, or 49 [Table 4].
8. The [synthetic] oligonucleotide, or analogue thereof, as set forth in claim 6 wherein the oligonucleotide comprises [segment has] a sequence as set forth in SEQ ID No: 45.
9. The [synthetic] oligonucleotide, or analogue thereof, as set forth in claim 1 [5] wherein the oligonucleotide comprises [has] a sequence corresponding to the [entire] sequence of the 3'-UTR of a human or mouse ribonucleotide reductase R2 mRNA [for the R2 component] as set forth in SEQ ID No: 2 [(SEQ ID No:2) of or segment thereof substantially free of the coding sequence of ribonucleotide reductase protein R2].
10. The [synthetic] oligonucleotide, or analogue thereof, as set forth in claim 9 wherein the oligonucleotide comprises [segment has] a sequence as set forth in SEQ ID Nos: 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, or 43 [Table 5].
11. The [synthetic] oligonucleotide, or analogue thereof, as set forth in claim 9 wherein the oligonucleotide comprises [segment has] a sequence as set forth in SEQ ID Nos: 6, 7, 8, 9, 10, 11, or [-]12.

12. A pharmaceutical composition for inhibiting [the] tumorigenicity of neoplastic cells in a human or mouse comprising [mammal consisting of] an effective amount of at least one oligonucleotide [active ingredient] as set forth in claim 1; and a pharmaceutically physiologically acceptable carrier or diluent.
13. A pharmaceutical composition for inhibiting [modulating] tumorigenicity of neoplastic cells in a human or mouse comprising [mammal consisting of] an effective amount of at least one oligonucleotide [active ingredient] as set forth in claim 6[, or the antisense sequence thereof, or a ribozyme comprising a sequence complementary to at least a portion of said UTR]; and a pharmaceutically physiologically acceptable carrier or diluent.
14. A pharmaceutical composition for inhibiting [modulating] tumorigenicity of neoplastic cells in a human or mouse comprising [mammal consisting of] an effective amount of at least one oligonucleotide [active ingredient] as set forth in claim 9[, or the antisense sequence thereof, or a ribozyme comprising a sequence complementary to at least a portion of said UTR]; and a pharmaceutically physiologically acceptable carrier or diluent.
15. A pharmaceutical composition for inhibiting metastasis of [a] neoplastic cells in a human or mouse comprising [mammal consisting of] an effective amount of at least one oligonucleotide [active ingredient] as set forth in claim 9[, or the antisense sequence thereof, or a ribozyme comprising a sequence complementary to at least a portion of said UTR]; and a pharmaceutically physiologically acceptable carrier or diluent.
16. A pharmaceutical composition for inhibiting [modulating] tumorigenicity of [a] neoplastic cells in a human or mouse comprising [mammal consisting of] an effective amount of at least two [active ingredients selected from] oligonucleotides, or analogues thereof, each comprising at least seven nucleotides having a sequence corresponding to the [entire] sequence of a 3'-UTR of a human or mouse ribonucleotide reductase R1 or R2, [the] mRNA, [for the R1 or R2 component or sequence segments of at least seven consecutive nucleotides thereof substantially free of the coding sequence of] ribonucleotide reductase protein R1 or R2 respectively or the antisense sequences